These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11051627)

  • 1. XIIIth International AIDS Conference: new thoughts on old drugs.
    Laurence J
    AIDS Patient Care STDS; 2000 Sep; 14(9):457-9. PubMed ID: 11051627
    [No Abstract]   [Full Text] [Related]  

  • 2. Simplifying HIV therapeutics, and the global treatment of AIDS.
    Laurence J
    AIDS Read; 2003 Jan; 13(1):5-6. PubMed ID: 12569889
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV prevention and treatment in Africa.
    Laurence J
    AIDS Patient Care STDS; 2000 Aug; 14(8):399-400. PubMed ID: 10977967
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiretroviral roll-out: the problem of second-line therapy.
    Boyd M; Emery S; Cooper DA
    Lancet; 2009 Jul; 374(9685):185-6. PubMed ID: 19616706
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV news from Buenos Aires: Part 1--the Zahir and the band-aid. 1st IAS conference on HIV pathogenesis and treatment. July 8-11, 2001, Buenos Aires.
    Mascolini M
    IAPAC Mon; 2001 Sep; 7(9):274-89. PubMed ID: 11708272
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pharmaco-economic aspects of HIV therapy. Savings with HAART].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():80. PubMed ID: 15011600
    [No Abstract]   [Full Text] [Related]  

  • 7. AIDS research. Drug trials without the drugs?
    Cohen J
    Science; 2003 May; 300(5623):1212-3. PubMed ID: 12764159
    [No Abstract]   [Full Text] [Related]  

  • 8. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).
    Gazzard B;
    HIV Med; 2005 Jul; 6 Suppl 2():1-61. PubMed ID: 16011536
    [No Abstract]   [Full Text] [Related]  

  • 9. [GlaxoSmithKline again lowers prices of drugs for HIV/AIDS and malaria].
    Krankenpfl J; 2002; 40(7-9):222-3. PubMed ID: 12514863
    [No Abstract]   [Full Text] [Related]  

  • 10. Do patents prevent access to drugs for HIV in developing countries?
    Goemaere E; Kaninda AV; Ciaffi L; Mulemba M; t Hoen E; Pécoul B
    JAMA; 2002 Feb; 287(7):841-2; author reply 842-3. PubMed ID: 11851569
    [No Abstract]   [Full Text] [Related]  

  • 11. Do patents prevent access to drugs for HIV in developing countries?
    Selgelid MJ; Schuklenk U
    JAMA; 2002 Feb; 287(7):842-3. PubMed ID: 11851570
    [No Abstract]   [Full Text] [Related]  

  • 12. Approaches to interrupting HAART for the treatment of HIV infection. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
    Dybul M;
    IAPAC Mon; 2001 Aug; 7(8):232-4. PubMed ID: 11708275
    [No Abstract]   [Full Text] [Related]  

  • 13. Balancing effectiveness and access to HIV treatment in the developing world.
    Hill A; Wood E
    AIDS; 2007 Jan; 21(3):361-3. PubMed ID: 17255743
    [No Abstract]   [Full Text] [Related]  

  • 14. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy).
    Farmer P; Léandre F; Mukherjee J; Gupta R; Tarter L; Kim JY
    Bull World Health Organ; 2001; 79(12):1145-51. PubMed ID: 11799447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutting the cost of South African antiretroviral therapy using newer, safer drugs.
    Venter WF; Kaiser B; Pillay Y; Conradie F; Gomez GB; Clayden P; Matsolo M; Amole C; Rutter L; Abdullah F; Abrams EJ; Casas CP; Barnhart M; Pillay A; Pozniak A; Hill A; Fairlie L; Boffito M; Moorhouse M; Chersich M; Serenata C; Quevedo J; Loots G
    S Afr Med J; 2016 Dec; 107(1):28-30. PubMed ID: 28112085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy for children in the routine setting in Malawi.
    Malawi Paediatric Antiretroviral Treatment Group
    Trans R Soc Trop Med Hyg; 2007 May; 101(5):511-6. PubMed ID: 17197006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access to HIV drugs: are we changing the two world paradigm?
    Lazzarini Z
    Conn J Int Law; 2002; 17(2):281-96. PubMed ID: 12688297
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children <5 years of age.
    Sauvageot D; Schaefer M; Olson D; Pujades-Rodriguez M; O'Brien DP
    Pediatrics; 2010 May; 125(5):e1039-47. PubMed ID: 20385636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. South Africa on the eve of the XIIIth International AIDS Conference.
    Laurence J
    AIDS Read; 2000 Jun; 10(6):328-30. PubMed ID: 10881358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.